JOURNAL OF THE CZECH PEDIATRIC SOCIETY AND THE SLOVAK PEDIATRIC SOCIETY

Čes-slov Pediat 2025, 80(90):39-44 | DOI: 10.55095/CSPediatrie2025/051

Country-wide register of pediatric growth hormone treatment recipients REPAR - a 2025 report

Aneta Kodytková, Jan Lebl, Stanislava Koloušková, skupina pro růstový hormon v pediatrii České endokrinologické společnosti*
Pediatrická klinika, 2. lékařská fakulta, Univerzita Karlova a Fakultní nemocnice v Motole, Praha

Since 2014, the Czech national registry REPAR has been collecting longitudinal data on patients treated with somatropin (recombinant human growth hormone; rhGH), and since 2023 also with long-acting growth hormone analogue somatrogon (Ngenla

®). Additionally, data from previous international database systems since

1992 have been incorporated into this registry - thus, it represents a nearly complete collection of patients receiving growth hormone in the Czech Republic since the initiation of rhGH

administration. As of January 1st, 2025, the paediatric module of REPAR registry contained data on 6009 children and adolescents, of these 3421 were reported directly to REPAR, and 2588 converted from earlier registries. The count of currently treated patients is 2289 (1414 boys; 875 girls) in seven approved indications - growth hormone deficiency (n=1101);

small for gestational age with persistent short stature in childhood (n=765); Turner syndrome (n=114); Prader-Willi syndrome (n=64); SHOX deficiency (n=53); Noonan syndrome (n=129); chronic kidney disease (n=21); and other or unspecified condition (n=43). Therapy was newly initiated in 335 paediatric patients within the year 2024. Median age at treatment onset was 5.4 years (P5-95: 0,5; 13,2).

The REPAR registry is a valuable data source to analyse efficacy and safety of growth hormone therapy.

Keywords: REPAR, registry, growth hormone, treatment, Czech Republic

Accepted: September 23, 2025; Published: September 1, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kodytková A, Lebl J, Koloušková S, hormon v pediatrii České endokrinologické společnosti SPR. Country-wide register of pediatric growth hormone treatment recipients REPAR - a 2025 report. Ces-slov Pediat. 2025;80(Suppl.3):39-44. doi: 10.55095/CSPediatrie2025/051.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. . Stochholm K, Kiess W. Long-term safety of growth hormone - a combined registry analysis. Clin Endocrinol (Oxf) 2018; 88: 515-528. Go to original source...
    2. . Ranke MB, Wit JM. Growth hormone - past, present and future. Nat Rev Endocrinol 2018; 14: 285-300. Go to original source...
    3. . Kodytková A, Zemková D, Koloušková S, et al. Růstové databáze a registry - cesta k poznání fyziologických účinků růstového hormonu. Čes-slov Pediat 2020; 75 (4): 252-257.
    4. . Ranke MB, Lindberg A, Chatelain P, et al. Predicting the response to recombinant human growth hormone in Turner syndrome: KIGS models. Acta Paediatr 1999; 433: 122-125. Go to original source...
    5. . Pfäffle R, Land C, Schönau E, et al. Growth hormone treatment for short stature in the USA, Germany and France: 15 years of surveillance in the Genetics and Neuroendocrinology of Short-stature International Study (GeNeSIS). Horm Res Paediatr 2018; 90: 169-180. Go to original source...
    6. . Sävendahl L, Polak M, Backeljauw P, et al. Treatment of children with GH in the United States and Europe: long-term follow-up from NordiNet® IOS and ANSWER program. J Clin Endocrinol Metab 2019; 104: 4730-4742. Go to original source...
    7. . Koledova E, Stoyanov G, Ovbude L, et al. Adherence and long-term growth: the easypod TM connect observational study (ECOS) in children with growth disorders. Endocr Connect 2018; 7: 1-30. Go to original source...
    8. . Kodytková A, El Lababidi E, Čermáková I, et al. Analýza dat z celostátního registru pacientů léčených růstovým hormonem REPAR. Čes-slov Pediat 2020; 75: 205-213.
    9. . Kodytková A, Toni L, Plachý L, et al. Pubertální růst dětí, které se narodily malé na svůj gestační věk (SGA), s malou výškou v dětství (SGA-SS). Výsledky léčby růstovým hormonem z dat české národní databáze REPAR. Čes-slov Pediat 2023; 78: 30-36. Go to original source...
    10. . Toni L, Kodytková A, Plachý L, et al. Dospělá výška dětí, které se narodily malé na svůj gestační věk (SGA), s malou výškou v dětství (SGA-SS). Výsledky léčby růstovým hormonem z dat české národní databáze REPAR. Čes-slov Pediat 2023; 78: 22-29. Go to original source...
    11. . Kodytková A, Amaratunga SA, El-Lababidi E, et al. Early-onset growth hormone treatment in Prader-Willi syndrome attenuates transition to severe obesity. J Pediatr Endocrinol Metab 2025; 38: 525-532. Go to original source...
    12. . Kodytková A, Dušátková P, Amaratunga SA, et al. Variant pubertal development in Prader-Willi syndrome: early and slow progression of pubarche with normal age at gonadarche. Front Endocrinol (Lausanne) 2025; 16: 1527140. Go to original source...
    13. . Lebl J, Šnajderová M. Současné indikace léčby růstovým hormonem v pediatrii. Pediatr praxi 2005; 2: 108.
    14. . Pricci F, Villa M, Maccari F, et al. The Italian registry of GH treatment: electronic Clinical Report Form (e‑CRF) and web‑based platform for the national database of GH prescriptions. J Endocrinol Invest 2019; 42: 769-777. Go to original source...
    15. . Polak M, Konrad D, Pedersen BT, et al. Still too little, too late? Ten years of growth hormone therapy baseline data from the NordiNet® International Outcome Study. J Clin Endocrinol Metab 2018; 31: 521-532. Go to original source...
    16. . Wigren M, Hansen S. Prader-Willi syndrome: clinical picture, psychosocial support and current management. Child Care Heal Dev 2003; 29: 449-456. Go to original source...
    17. . Baars J, Van den Broecka J, le Cessiec S, et al. Body mass index in growth hormone deficient children before and during growth hormone. Horm Res 1998; 49: 39-45. Go to original source...
    18. . Hokken-Koelega A, van Pareren Y, Sas T, et al. Final height data, body composition and glucose metabolism in growth hormone-treated short children born small for gestational age. Horm Res 2003; 60: 113-114. Go to original source...
    19. . Ranke M, Lindberg A. Growth hormone treatment of short children born small for gestational age or with Silver-Russell syndrome: results from KIGS (Kabi International Growth Study), including the first report on final height. Acta Paediatr 1996; 417: 18-26. Go to original source...
    20. . Donaldson M. Growth hormone therapy in Turner syndrome - current uncertainties and future strategies. Horm Res 1997; 48: 35-44. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content